Adjuvant Chemotherapy With Paclitaxel and Cisplatin in Lymph Node-Positive Thoracic Esophageal Squamous Cell Carcinoma
Status:
Completed
Trial end date:
2014-05-01
Target enrollment:
Participant gender:
Summary
Esophageal cancer is a highly aggressive malignancy with a poor overall outcome.
- Five year survival rate after radical esophagectomy is modest at about 40%.The patients
with regional lymph node metastases have worse outcome than those without lymph node
metastases.
- No standard postoperative adjuvant chemotherapy has ever been established.